MeiraGTx (NASDAQ:MGTX – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and price targets for MeiraGTx and Stoke Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 0 | 3 | 5 | 1 | 2.78 |
| Stoke Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
MeiraGTx currently has a consensus target price of $24.71, indicating a potential upside of 166.32%. Stoke Therapeutics has a consensus target price of $44.25, indicating a potential upside of 83.08%. Given MeiraGTx’s higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than Stoke Therapeutics.
Risk and Volatility
MeiraGTx has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Profitability
This table compares MeiraGTx and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | 19.87% | 283.85% | 29.39% |
| Stoke Therapeutics | -753.60% | -59.36% | -51.46% |
Institutional and Insider Ownership
67.5% of MeiraGTx shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares MeiraGTx and Stoke Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $81.39 million | 10.95 | -$114.20 million | $0.71 | 13.07 |
| Stoke Therapeutics | $184.42 million | 8.46 | -$6.89 million | ($3.34) | -7.24 |
Stoke Therapeutics has higher revenue and earnings than MeiraGTx. Stoke Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Summary
MeiraGTx beats Stoke Therapeutics on 9 of the 14 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
